20170425 PR Q1-2017
Category: Press release
Transgene and Bristol-Myers Squibb Announce Clinical Research Collaboration to Evaluate TG4010 in Combination with Opdivo and Standard Chemotherapy in First Line Non-Small Cell Lung Cancer
20170425 BMS-Clinical Collaboration Release Transgene-FINAL
SillaJen and Transgene Announce the Enrollment of the First European Patient in Multinational Phase 3 Trial for Pexa-Vec in Advanced Liver Cancer
20170424 PR PHOCUS FPI EU – EN
Marie Landel and Maya Said Nominated to be Independent Members of Transgene’s Board of Directors
20170419 TG Appointments Board EN
Transgene and Institut Bergonié Start the Phase 2 Part of the METROmaJX Trial
20170412 PR Metro-JX Ph2 EN
Transgene Announces Upcoming Investor Meetings and R&D Day
20170410 PR Next investor events
Transgene Presents Very Promising New Immunology Data of its Next Generation Armed Oncolytic Virus at the AACR Annual Meeting in Washington, DC
20170330-AACR poster EN
Major achievements in 2016 validate Transgene’s strategy and provide promising outlook for 2017
20170320 2016 Resultats annuels EN
First Patient dosed in Phase 2 Trial Evaluating Transgene’s TG4010 in Combination with Opdivo® (nivolumab) for 2nd Line Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC)
20170313 FPI Kelly study EN
Transgene and Léon Bérard Cancer Center Announce Dosing of the First Patient in a Phase 1 Immunotherapy Clinical Trial Evaluating the Intra-Tumoral Co-Administration of Pexa-Vec plus Ipilimumab (Yervoy®) in Solid Cancers
20170213 ISI-JX FPI EN final